Intangible Assets

6 Months Ended

Oct. 18, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedules of finite-lived intangible assets:



	October 18, 2015			April 24, 2015
Developed Technology Rights (1)	$	13,904,000		$	13,204,000
Other Intangible Assets (2)	868,000			1,023,000
Total	14,772,000			14,227,000
Accumulated amortization	(4,370,077		)	(4,058,761		)
Net	$	10,401,923		$	10,168,239

(1)

Developed Technology Rights include purchased patents, related know-how, and licensed patent rights. These assets relate primarily to seizure detection and response, wireless communication technology, the treatment of obstructive sleep apnea and conditionally safe magnetic resonance (“MR”) technology for implantable leads. During the twelve week period ended October 18, 2015, we purchased intangible assets for MR technology for implantable leads of $1.0 million.


(2)	Other Intangible Assets primarily consist of purchased clinical neurological and sleep apnea databases.

The weighted average amortization period in years for our intangible assets at October 18, 2015:



Developed Technology Rights	15
Other Intangible Assets	12

Aggregate intangible asset amortization was $766,000 and $562,000 for the twenty-five and twenty-six weeks ended October 18, 2015 and October 24, 2014, respectively, which was reported in either research and development expense or cost of goods sold in the consolidated statement of income.

The estimated future amortization expense based on our finite-lived intangible assets at October 18, 2015:




Fiscal year 2016 (remaining 28 weeks)	$	536,797
Fiscal year 2017	1,026,400
Fiscal year 2018	1,046,284
Fiscal year 2019	1,066,337
Fiscal year 2020	686,256
Fiscal year 2021 (53 week period)	686,256
Thereafter	5,353,593